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SUMMARY
STING gain-of-function causes autoimmunity and immunodeficiency in mice and STING-associated vascul-
opathy with onset in infancy (SAVI) in humans. Here, we report that STING gain-of-function in mice prevents
development of lymph nodes and Peyer’s patches.We show that the absence of secondary lymphoid organs
is associatedwith diminished numbers of innate lymphoid cells (ILCs), including lymphoid tissue inducer (LTi)
cells. Althoughwild-type (WT) a4b7+ progenitors differentiate efficiently into LTi cells, STING gain-of-function
progenitors do not. Furthermore, STING gain-of-function impairs development of all types of ILCs. Patients
with STING gain-of-function mutations have fewer ILCs, although they still have lymph nodes. In mice,
expression of the STING mutant in RORgT-positive lineages prevents development of lymph nodes and re-
duces numbers of LTi cells. RORgT lineage-specific expression of STING gain-of-function also causes lung
disease. Since RORgT is expressed exclusively in LTi cells during fetal development, our findings suggest
that STING gain-of-function prevents lymph node organogenesis by reducing LTi cell numbers in mice.
INTRODUCTION
Stimulator of interferon genes (STING) is a cytosolic sensor of cy-
clic dinucleotides that are produced by the host (e.g., cGAMP) or
bacteria (e.g., c-di-GMP, c-di-AMP, cGAMP) (Ablasser et al.,
2013; Burdette et al., 2011; Sun et al., 2013; Whiteley et al.,
2019). Gain-of-function mutations in STING cause a systemic
autoinflammatory disease known as STING-associated vascul-
opathywith onset in infancy (SAVI) (Liu et al., 2014).We previously
generated heterozygous STING N153S mice that have a SAVI-
associated mutation (Warner et al., 2017). STING N153S mice
can only be studied as heterozygous animals since homozygous
expression of STING N153S causes early embryonic lethality
(Warner et al., 2017). Similar to humans with SAVI, heterozygous
STING N153S mice develop systemic inflammation and lung dis-
ease aswell as T cell cytopenia (Luksch et al., 2019;Warner et al.,
2017). However, unlike humans with SAVI, STING N153S mutant
mice develop severe combined immunodeficiency (Bennion
et al., 2019). The mechanisms of immunodeficiency associated
with STING gain-of-function are incompletely understood.
During infection with g-herpesvirus-68 (gHV68), heterozygous
STING N153S mice fail to adequately generate antigen-specific
CD8+ T cells and virus-specific immunoglobulin G (IgG) (Bennion
et al., 2019). Indeed, STING N153S animals exhibit greater viral
burden than Rag1/ animals, which completely lack B cells
and T cells (Bennion et al., 2019). In addition to defects in adap-
tive immunity, STING N153S causes an innate immunodefi-
ciency (Bennion et al., 2019). Although STING gain-of-function
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has previously been studied in T cells and myeloid cells, the
impact of constitutive STING signaling in innate lymphoid cells
is less well defined.
Here, we report that the STING N153S gain-of-function muta-
tion prevents the development of lymph nodes (LNs) and Peyer’s
patches in mice. This developmental defect is associated with
reduced numbers of all types of ILCs, including lymphoid tissue
inducer (LTi) cells. Furthermore, a4b7+ progenitor cells from
STINGN153Smice lack the capacity to differentiate into LTi cells
in an OP9 cell culture system. To define cell-type-specific effects
of STING gain-of-function on LN development, we generated
mice that express STING N153S in RORgT-positive lineages
(e.g., LTi cells in the fetus and in ILC3s and T cells in the adult).
Like global STING N153S knock-in mice, these cell-type-spe-
cific transgenic mice lack LNs, have reduced numbers of mature
LTi cells, and develop autoimmune lung disease. Thus, expres-
sion of STING N153S in RORgT-positive lineages prevents
lymphoid tissue organogenesis in mice.
RESULTS
Absence of LNs and Peyer’s Patches in STING N153S
Mice
We discovered that heterozygous STING N153S mice lack LNs
and Peyer’s patches (Figure 1). Independently generated STING
N153S mice, produced using a different guide RNA and DNA
oligo donor (Luksch et al., 2019), also were found to lack LNs
(data not shown). Additionally, mice with a neighboring gain-of-
function mutation (STING V154M) were reported to lack LNs,
although the severity of the defect and mechanism was not
described (Bouis et al., 2019). Therefore, we began to quantitate
LNs in heterozygous STING N153S and wild-type (WT) littermate
control animals by performing subcutaneous injection of Evans
Blue dye, which accumulates in draining lymphatics and LNs
(Harrell et al., 2008). This confirmed the absence of visually
apparent LNs (Figures 1A and 1B). Serial sectioning of inguinal
fat pads (Figure 1C) and the small intestine (Figure 1D), followed
by hematoxylin and eosin (H&E) staining, did not reveal histolog-
ical evidence of even rudimentary LNs or Peyer’s patches. We
quantitated the numbers of cervical, inguinal, axillary, brachial,
and mesenteric LNs and found a small mesenteric or inguinal
LN in only 10% of animals (Figure 1E). In addition to our histo-
logical assessment of the intestine (Figure 1D), there were no
visible Peyer’s patches in STING N153S mice (Figure 1F). Since
Peyer’s patches are an important site of IgA production (Craig
and Cebra, 1971; Reboldi et al., 2016), we measured IgA levels
in the serum and the stool of WT and STING N153S animals.
We found that STING N153S mice had no detectable IgA in the
serum or in stool, in contrast to co-housed WT littermate control
mice that had normal levels of IgA (Figure 1G) (Fransen et al.,
2015; Klein-Schneegans et al., 1989). Thus, the autosomal domi-
nant STING N153S mutation interferes with LN and Peyer’s
patch development in mice, and this likely contributes to
STING-N153S-associated immunodeficiency (Bennion et al.,
2019).
Rag1/ mice have small LNs that can be difficult to visualize
(Mombaerts et al., 1992), but Rag1/ mouse LNs become
easier to visualize following adoptive transfer of lymphocytes.
Thus, if STING N153S mice had rudimentary LNs, they might
become visible after adoptive transfer. After adoptive transfer
of splenocytes, we confirmed that Rag1/ LNs were indeed
visible (Figures S1A and S1B). In contrast, we found that
Rag1/ STING N153S recipient mice still had no visually
apparent LNs after adoptive transfer (Figures S1A and S1B).
To determine whether the cyclic GMP-AMP synthase (cGAS)-
STING pathway and subsequent signaling through the type I
interferon (IFN) receptor (IFNAR1) is involved in this develop-
mental defect, we crossed STING N153S animals to mice lack-
ing cGAS, the IFN-regulatory factors 3 and 7 (IRF3 and IRF7),
or IFNAR1. Similar to our prior observation of IFNAR1-indepen-
dent lung disease (Luksch et al., 2019), none of these genetic
knockouts were sufficient to rescue the LN or Peyer’s patch defi-
ciency (Table S1). Thus, STING N153S disrupts LN and Peyer’s
patch formation independently of cGAS and IFNAR1 signaling.
This is consistent with what we know about spontaneous auto-
inflammatory disease pathogenesis in STING N153S animals,
which occurs independently of cGAS, IFNAR1, IRF3, and IRF7
(Luksch et al., 2019; Warner et al., 2017). Others also have
confirmed that disease in STING gain-of-function mice develops
independently of IFNAR1 (Bouis et al., 2019; Motwani et al.,
2019).
STING N153S Reduces Numbers of All Types of ILCs,
Including LTi Cells
LN development requires LTi cells, which are a type of ILC3
(Sawa et al., 2010). To test whether STING N153S has an effect
on ILCs, we quantitated intestinal ILCs in 6-to-7-week-old
STING N153S mice and WT littermate control animals (Fig-
ure 1H). In the adult small intestine, we observed a reduced fre-
quency of ILC1s and natural killer (NK) cells, as well as ILC3s,
and an increased frequency of ILC2s (Figures 1I–1K). Upon
quantitation of absolute numbers of ILCs, all types of ILCs
were reduced in the STING N153S small intestine (38-fold
fewer ILC1s and NK cells, 2.9-fold fewer ILC2s, and 28-fold
fewer ILC3s than in WT; p < 0.005 for ILC2s and p < 0.0001 for
ILC1s and ILC3s) (Figures 1I–1K). Thus, STING N153S has a
large effect on development and/or survival of all three groups
of ILCs in the adult small intestine. LTi-like ILC3s, defined by
expression of CCR6 (Klose et al., 2013; Rankin et al., 2013;
Sawa et al., 2010; Vonarbourg et al., 2010), exhibited a 41-
fold reduction in STINGN153Smice compared toWT littermates
(Figure 1L). In the STING N153S spleen, ILC numbers also were
globally reduced. To distinguish between NK cells and ILC1s, we
performed EOMES staining, which confirmed that there were
fewer ILC1s (1.7-fold reduction, p < 0.05) and NK cells in STING
N153Smice (30.2-fold reduction, p < 0.0001) (Figures S1C–S1E).
We hypothesized that STING N153Smay result in a deficiency
of committed ILC progenitors, leading to reduced numbers of
mature ILCs. However, STING N153S had no effect on the num-
ber of alpha-lymphoid progenitor (aLP) cells, which are precur-
sors to all types of ILCs. Furthermore, there was no difference
in the numbers of common helper-like innate lymphoid cell pro-
genitors (CHILPs) 1 or CHILP2 cells (Figures S1F–S1J), which are
precursors to specific subsets of ILCs (Constantinides et al.,
2014; Klose et al., 2014). NK cells have distinct progenitors
known as refined NK-cell progenitors (Fathman et al., 2011).
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Figure 1. Absence of Lymph Nodes and Peyer’s Patches in STING N153S Mice
(A and B) Representative photographs ofWT (left panels) and STINGN153S (right panels) animals 15min after unilateral, subcutaneous footpad injection of Evans
Blue dye. Inguinal lymph nodes (LNs) are shown in (A), and retroperitoneal LNs are shown in (B). Discernible LNs are marked by black arrows.
(C) Representative H&E staining of serial skin sections and inguinal fat pads of WT and STING N153S mice. Images are representative of 20 sections per mouse
from three mice per genotype from two independent experiments. Scale bar: 200 mm.
(D) Representative H&E staining of serial sections from the small intestines of WT and STING N153S mice. n = 3 mice from two independent experiments. Scale
bar: 200 mm.
(E and F) Total number of discernible cervical, inguinal, brachial, axillary, and mesenteric LNs (E) and Peyer’s patches (F). Data represent the mean of six STING
N153S and six WT littermate control mice.
(G) IgA levels in the serum and stool of STING N153S and WT littermate animals were quantitated by ELISA. Data represent the mean of eight samples per
genotype. Dashed line denotes the limit of detection.
(H–L) Flow cytometric analysis of intestinal leukocytes of 6-to-7-week-old STING N153S mice and WT littermate control animals. (H) Representative FACS dot
plots of intestinal leukocytes, indicating the gating strategy for ILC2, ILC3, and LTi-like CCR6+ ILC3 populations. Numbers (red text) indicate the percent of
CD45+Lin cells in each gate (lineage markers: CD19, CD5, and CD3). Percent and total number of ILC1 and NK cells (NKp46+GATA3RORgT) (I), ILC2s (J),
ILC3s (K), and LTi-like CCR6+ ILC3s (L).
Data represent the mean from n = 6 animals per genotype. All data were pooled from at least two independent experiments. Results were analyzed by Mann-
Whitney U test. *p < 0.05; **p < 0.01; ***p < 0.001.
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STING N153S diminished the numbers of refined NK-cell pro-
genitors (3.7-fold reduction, p < 0.001) in the bone marrow of
STING N153S animals (Figures S1K–S1M). Thus, STING
N153S reduces the number of refined NK-cell progenitors, but
not other ILC progenitor cells in the bone marrow. Collectively,
these results suggest that STING N153S preferentially impacts
mature ILCs.
STING N153S Mouse Spleens Have B Cell Zones and
Express Chemokines Known to Regulate Splenic
Organization
STING N153S mice have splenomegaly and exhibit histological
abnormalities of the spleen (Luksch et al., 2019; Warner et al.,
2017). To more carefully evaluate the spleens of STING S153S
animals, we performed histological staining and flow cytometry.
Consistent with prior reports (Luksch et al., 2019; Warner et al.,
2017), histological analysis of STING N153S and WT littermate
spleens revealed disorganized architecture (Figure S2A). How-
ever, unlike IkBa mutant mice that lack LNs (Mooster et al.,
2015), we found that the mucosal addressin cell adhesion mole-
cule (MADCAM-1)-expressing marginal sinus remained intact in
the STINGN153S spleen (Figure S2B). Immunofluorescent stain-
ing of CD3 revealed that T cell zones were absent in STING
N153S spleens (Figure S2C), a finding that may reflect a large
reduction in T cell numbers (Warner et al., 2017). Flow cytometric
analysis of STING N153S and WT littermate splenocytes re-
vealed no difference in the number of follicular dendritic cells
(FDCs), a 5-fold increase in fibroblastic reticular cells (FRCs) in
STING N153S spleens, and no difference in the numbers of
WT and STING N153S endothelial cells (Figures S2D–S2G).
Furthermore, we confirmed expression of the chemokines
CCL19 and CCL21, which organize T cell zones (Dieu et al.,
1998; Gunn et al., 1998; Luther et al., 2000), as well as the B-
cell-attracting chemokine CXCL13, which is produced by
FDCs (Figure S2H) (Cyster et al., 2000). Thus, STING N153S
does not create a deficiency of splenic FDCs or FRCs, which
regulate lymphoid tissue organization.
STINGN153SMiceHave Fewer LTi Cells in Fetal Tissues
Because adult STING N153S mice have fewer ILCs and LTi-like
cells, we hypothesized that STING N153S fetuses would also
have fewer LTi cells, which are required for LN organogenesis.
Indeed, in STING N153S fetuses, we observed a reduction in
the percent and number of gut LTi cells (4.5-fold reduction,
p < 0.0001) (Figures 2A and 2B). CD4 is used as a surrogate
marker for LTi cells in embryonic LN anlagen, since most CD4+
cells in developing LNs represent CD3RORgT+ LTi cells (Eberl
et al., 2004; Kelly and Scollay, 1992). Histological analysis of cer-
vical LN anlagen from embryonic day 18.5 (E18.5) STING N153S
and WT littermate fetuses revealed diminished CD4 staining in-
tensity, suggesting a reduced accumulation of LTi cells (Figures
2C and 2D). There was no difference in the intensity of VCAM-1
staining, a marker of lymphoid tissue organizer (LTo) cells, or in
the two-dimensional size of the LN anlagen (Figures 2E and
2F). Thus, the STING N153S mutation reduces the accumulation
of LTi cells in the fetal gut and LN anlagen.
LTi cells activate noncanonical NF-kB signaling in LTo cells by
engaging the lymphotoxin-b receptor (LTbR), leading to signaling
events required for LN development (Mooster et al., 2015; Onder
et al., 2013; Rennert et al., 1998). Therefore, we set out to test
whether non-canonical NF-kB signaling downstream of the
LTbR is intact in STING N153S cells. Mouse embryonic fibro-
blasts (MEFs) have previously been used to study LTbR signaling
(Dejardin et al., 2002; Mooster et al., 2015), so we generated
MEFs and treated them with a monoclonal antibody (mAb)
agonist of LTbR or isotype control mAb, as described previously
(Dejardin et al., 2002). SDS-PAGE and western blot of IkBa and
RelB revealed no differences in NF-kB activation downstream of
LTbR (Figure S2I). Treatment ofWT andSTINGN153SMEFswith
the LTbR agonist antibody caused a similar upregulation of
genes that contribute to lymphoid tissue organogenesis,
including Vcam1, Icam1, Madcam1, and Cxcl10 (Figures S2J–
S2M), which are upregulated downstream of LTbR signaling (Ca-
posio et al., 2007; Dejardin et al., 2002; Hoffmann et al., 2003;
Mooster et al., 2015). Thus, LTbR-mediated noncanonical NF-
kB signaling remains intact in STING N153S MEFs, suggesting
that LTbR signaling is not dysregulated by the mutation.
Single-Cell RNA Sequencing of a4b7+ Cells from the
Fetal Liver Suggests Fewer Mature LTi Cells in STING
N153S Fetuses
To confirm that a4b7+ cells from WT and STING N153S fetal
livers (Figure 3A) express STING as well as transcription factors
known to impact ILC differentiation, we performed fluorescence-
activated cell sorting sequencing (FACS-seq), a type of single-
cell RNA sequencing. We detected STING (Tmem173) gene
expression in at least a subset of a4b7+ cells (Figure 3B) and
additionally confirmed that there was no difference in expression
of Id2 and Tox, transcription factors required for LN development
(Figures 3C and 3D) (Aliahmad et al., 2010; Cupedo and Mebius,
2005). However, a4b7+ cells from STING N153S fetuses ex-
pressed higher levels of Tcf7, a gene highly expressed in early
lymphoid progenitors (Figure 3E) (Yang et al., 2015). This may
suggest that there are fewer mature a4b7+ cells in STING
N153S fetal livers than in theWT control livers. Using flow cytom-
etry, we confirmed similar expression levels of ID2, TOX, and
NFIL3, all of which are involved in a4b7+ progenitor cell differen-
tiation into mature LTi cells (Figures 3F–3I) (Aliahmad et al., 2010;
Cherrier et al., 2012; Geiger et al., 2014; Yokota et al., 1999).
Additionally, FACS-seq did not reveal differences in the expres-
sion of type-I-IFN-stimulated genes (Figure S3A). Finally, no
other genes known to be involved in LTi cell differentiation and
function were appreciably affected (Figure S3B) (Chea et al.,
2016). Thus, our FACS-seq and flow cytometric analyses
confirmed that STING is expressed in at least a subset of
a4b7+ cells, but without impacting the expression of most key
transcription factors involved in LN and ILC development.
STING N153S Impairs Generation of a4b7+ Progenitors
into LTi Cells and ILCs
Increased expression of Tcf7 may reflect the differentiation sta-
tus of a4b7+ cells in the fetal liver (Yang et al., 2015), consistent
with what we observed in the fetal gut (Figure 2B). To begin to
determine whether STING N153S impacts the differentiation of
ILCs, we assessed the capacity of WT and STING N153S
a4b7+ cells to differentiate into mature ILCs cells for 6 or
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14 days in an OP9 stromal cell culture system in the presence
of interleukin-7 (IL-7) and stem cell factor (SCF) (Cherrier et al.,
2012). On day 6, only 5% of Lin (CD19CD3) STING N153S
cells were LTi cells, compared with 50% in the WT cell culture
(Figures 4A, top panels, and 4B). We also detected a higher
percentage of NK cells and ILC2s in STING N153S cell cultures
compared with WT controls (Figures 4A, bottom panels, and
4B). Cell-intrinsic nucleic acid sensing may direct T cells into
Figure 2. STING N153S Reduces Numbers of LTi Cells in Fetal Tissues as Well as Their Accumulation in Developing LN Anlagen
In (A) and (B), leukocytes were harvested from the fetal gut on E16.5–E18.5 and analyzed by flow cytometry. In (C)–(F), frozen sections of cervical LN anlagen of
E18.5 fetuses were analyzed by widefield fluorescence microscopy.
(A) Representative FACS dot plots of LinCD45+CD127+cKIT+ cells isolated from the fetal gut. Numbers indicate the percent of events in each gate.
(B) Total number a4b7+RORgT+ LTi cells in the fetal gut on E16.5–E18.5. Data represent the mean of n = 20–23 fetuses per genotype pooled from three inde-
pendent experiments.
(C) Cervical LN anlagen sections were stained with DAPI and with antibodies against VCAM-1 (left panel) and CD4 (middle panel). Scale bar: 40 mm.
(D) Quantitation of CD4 staining intensity relative to the size of LN anlagen, defined as the total area of VCAM-1 and CD4 staining.
(E) Quantitation of VCAM-1 staining intensity relative to the size of LN anlagen.
(F) Quantitation of the size of LN anlagen, based on merged VCAM-1 and CD4 staining of WT and STING N153S cervical LN anlagen on E18.5.
Quantitation is from n = 7–9 cervical LN anlagen per genotype from two independent experiments. FACS data were analyzed by unpaired t test, and immu-
nofluorescence data were analyzed by Mann-Whitney U test. *p < 0.05; ****p < 0.0001.
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a T helper 2-type lineage (Imanishi et al., 2014), and an increase
in ILC2 and NK cell frequency may suggest that STING gain-of-
function biases ILC progenitors into helper ILC lineages. On
day 6, we observed 6.5-fold fewer STING N153S ILC1s and
2.6-fold fewer ILC2s compared with WT controls. However,
there was a much larger effect on the number of ILC3s (21-
fold) and LTi cells (145-fold) in STING N153S cultures (Figures
4C–4G). Since STING N153S impairs the differentiation of mul-
tiple ILC subsets after 6 days in the OP9 stromal cell system,
we reasoned that a longer experiment (14 days) may elucidate
whether this reflects a delay in differentiation. In contrast to
what was observed on day 6, we found no difference in the
numbers of WT and STING N153S ILC1s and ILC2s on day
14. However, the numbers of ILC3s and LTi cells were still
reduced in STING N153S cultures compared with WT controls
(10-fold and 8.6-fold, p < 0.0001 and p < 0.001) (Figure S4).
Thus, STING N153S delays the differentiation of ILC1s, ILC2s,
ILC3s, and LTi cells in a cell culture system but has its largest
effect on ILC3s and LTi cells (Figure 4H). This result is consis-
tent with our in vivo findings demonstrating a preferential effect
of STING N153S on ILC3s and LTi cells in mice (Figures 1H–1L
and 4H).
STING gain-of-function mutations cause apoptosis of
T cells (Gulen et al., 2017; Wu et al., 2019), so we hypothe-
sized that STING N153S may similarly cause apoptosis of
ILCs. However, we observed no difference in the percent or
number of annexin V-positive or annexin V-negative
a4b7+CD127+ cells, which represent a mixture of mature LTi
and LTi progenitor cells (Figures S5A–S5C). STING gain-of-
function mutations also reduce the proliferative capacity of
T cells (Cerboni et al., 2017), but bromodeoxyuridine (BrdU)
labeling in vivo did not reveal any differences in the percent
or number of proliferating LTi cells (Figure S5D). We reasoned
that dead or dying cells may be difficult to detect in vivo, so
we also tested for apoptosis of ILCs in the OP9 co-culture
system. We observed a small increase in the frequency of to-
tal dead cells in the STING N153S culture when compared to
WT samples (Figures S5E–S5G). Thus, STING N153S may
produce subtle effects on apoptosis of ILCs, although we
only detected this effect in cell culture and not in cells freshly
isolated from mice.
Human SAVI Patients Have Diminished Frequencies of
ILCs in Peripheral Blood
To test whether STING gain-of-function affects ILCs in humans
with SAVI, we performed flow cytometric analysis of peripheral
blood mononuclear cells (PBMCs). In healthy control subjects,
circulating ILCs represent approximately 0.1% of total CD45+
cells; are myeloid-, T-, B-, and NK-cell lineage negative; and
express CD7 and CD127 (IL-7R) (Hazenberg and Spits, 2014;
Lim et al., 2017). The two main peripheral blood ILC subsets
include CRTH2+ ILC2s, some of which express CD117, and
ILC precursors (ILCPs) that express CD117 but not CRTH2
(Lim et al., 2017; Mjösberg et al., 2011). A minor subset of
CD117CRTH2 ILCs (also referred to as ILC1) has been re-
ported (Roan et al., 2016; Spits et al., 2016), although the iden-
tity of this rare subset is the subject of ongoing study (Bernink
et al., 2017; Simoni et al., 2017). To determine whether humans
with STING gain-of-function mutations have an ILC deficiency,
we performed FACS analysis on healthy donor and SAVI pa-
tient PBMCs. Five unique SAVI patient samples with either
the N154S, V155M, or R281Q mutations were analyzed. Four
patients were being treated with a JAK1/2 inhibitor, and one
was being treated with mycophenolate mofetil (MMF) (Fig-
ure 5A). Obtaining samples from patients with untreated dis-
ease was not possible for ethical reasons. Frequencies of
Figure 3. Gene Expression and Transcrip-
tion Factor Analysis of STING N153S a4b7+
Fetal Liver Progenitor Cells
In (A)–(H), fetal livers were harvested on E14.5 from
WT and heterozygous STING N153S animals.
(A) Illustration depicting a4b7+ fetal liver cells and
their key transcription factors.
(B–E) a4b7+ cells were single-cell sorted by FACS
into 96 well plates, followed by RNA sequencing
(FACS-seq). Violin plots of FACS-seq results
demonstrating expression levels of Tmem173
(STING) (B), Id2 (C), Tox (D), and Tcf7 (E) in a4b7+
progenitor cells. Data represent the mean number
of counts per gene from 48 cells per genotype
performed as a screening experiment.
(F) Total number of a4b7+ cells (LinCD45+cK-
ITintCD127+a4b7+) in WT and STING N153S fetal
livers.
(G–I) Mean fluorescence intensity (MFI) of the
transcription factors ID2 (G), TOX (H), and NFIL3 (I)
in a4b7+ cells from the fetal livers of WT and STING
N153S mice.
Data in (E)–(H) represent the mean of n = 20–24 (F),
n = 13 (G), n = 6–9 (H), and n = 5–11 (I). Data in (F)–(I)
were pooled from at least two independent ex-
periments and analyzed by unpaired t test. *p <
0.05; **p < 0.01.
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LinCD7+ cells were similar in healthy control and JAK-inhibi-
tor-treated SAVI patients (Figure 5B). However, patients with
STING gain-of-function exhibited a 3-fold reduction in the fre-
quency of circulating total ILCs and ILC2s (Figures 5C–5E).
Thus, STING gain-of-function reduces the numbers of circu-
lating ILCs, consistent with a prior report that numbers of circu-
lating NK cells are reduced in patients with STING gain-of-func-
tion mutations (Liu et al., 2014). Since SAVI patients have LNs,
which we confirmed histologically (Figures S6A and S6B), our
results indicate that the effects on lymphoid organogenesis
only occur in mice. This may suggest species-specific differ-
ences in the effects of STING gain-of-function in LTi cells.
Studies of LTi cells in this rare patient population were not
possible.
Cell-Type-Specific Expression of STING Gain-of-
Function in RORgT+ Lineages Causes T Cell Cytopenia
and Lung Disease
Next, we set out to examine whether the expression of STING
N153S in mature LTi cells might be sufficient to reduce the num-
ber of LTi cells and prevent LN development in mice. We gener-
ated transgenic LoxP-STOP-LoxP STING N153S (floxed-STOP
STING N153S) mice where Cre-mediated recombination leads
to expression of the STING N153S mutant (Figure 6A). RORgT
is expressed specifically in LTi cells in the developing fetus
(Sun et al., 2000). In adult mice, RORgT is expressed in LTi-like
cells, ILC3s, Th17 cells, and T cells at the double-positive (DP)
stage of development (Sawa et al., 2010; Sun et al., 2000; Taka-
tori et al., 2009). We crossed the floxed-stop STING N153Smice
Figure 4. STING N153S Fetal Liver a4b7+ Progenitor Cells Do Not Differentiate into LTi Cells after 6 Days in an OP9 Cell Culture System
a4b7+ progenitor cells from the fetal liver were co-cultured with OP9 stromal cells, SCF, and IL-7. Cells were allowed to differentiate for 6 days and analyzed by
FACS.
(A) Representative FACS plots of adultWT (left panels) and STINGN153S (right panels) CD45+CD3CD19 cells. Cell frequencies within each gate are denoted in
red, and cell population names are labeled in blue.
(B) Average frequencies of ILC and a4b7+ cell populations as a fraction of total CD45+CD3CD19 cells.
(C–G) Percent and number of ILC1 (C), NK cells (D), ILC2 (E), ILC3 (F), and LTi-like cells (G).
(H) Graphical summary of the fold reduction in numbers of ILCs by STING N153S compared to WT.
Data represent themean of 6–10 replicates per group pooled from at least two independent experiments. Results were analyzed by unpaired t test. *p < 0.05; **p <
0.01; ****p < 0.0001.
Figure 5. Quantitation of ILC and ILC Progenitor Cells in the Blood of Human SAVI Patients
(A) Gating strategy and representative FACS plots of peripheral blood ILCP and ILC2 populations gated on the CD45+ live lymphocytes.
(B–E) Percent of total ILC & NK cells (LinCD7+) (B), total ILCs (CD56CD127+CD94NKG2ACD16CD2) (C), ILCP (CD117+CRTH2) (D), and ILC2
(CD117intCRTH2+) (E) as a frequency of CD45 live lymphocytes. Black dots (12 donors, left columns) denote healthy donors, purple dots (4 patients, middle
columns) denote SAVI patients on JAK inhibitors (ruxolitinib), and yellow dots (1 patient, right columns) denote a SAVI patient on mycophenolate mofetil (MMF).
Results were analyzed using unpaired t test. **p < 0.01.
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to transgenic RORgT-Cre animals and confirmed excision of the
STOP cassette in DP but not double-negative (DN) thymocytes
(Figure 6B). We previously found that ab T cells drive STING-
N153S-associated lung disease (Luksch et al., 2019), but we
did not examine whether the expression of the mutant in
T cells was sufficient to cause disease. Here, we found that
STING N153S expression induced by RORgT-Cre was sufficient
to cause perivascular lung inflammation in 13-week-old mice
(Figure 6C), suggesting that the expression of STING N153S in
T cells may be necessary and sufficient for certain features of
disease in STING N153S mice. Flow cytometric analysis of thy-
mocytes from 3-to-4-week-old RORgT-Cre+ floxed-stop STING
N153S mice and Cre-negative littermate control animals re-
vealed a reduced frequency of single-positive T cells, but not
DNor DP T cells, in RORgT-Cre-positivemice (Figure 6D). STING
N153S expression resulted in an increase in the percent of DP
thymocytes but without affecting DN thymocytes (Figures 6E,
6F, and S7A–S7D). This likely reflects a block in T cell differenti-
ation caused by the expression of STING N153S at the DP stage
(Figure 6F). Indeed, there was a corresponding reduction in the
percent and number of both CD4+ and CD8+ single-positive
T cells expressing the STING N153S mutant (7-fold reduction
in CD4+ T cells, p < 0.001; 2-fold reduction in CD8+ T cells,
p < 0.01) (Figures 6G and 6H). Thus, STING N153S expression
at the DP stage causes a reduction in the number of single-pos-
itive thymocytes without impacting the numbers of DN thymo-
cytes. Flow cytometric analysis of splenocytes confirmed an ef-
fect of cell-type-specific expression of STING N153S on
numbers of T cells but not B cells or myeloid cells (Figures 6I–
6L and S7E–S7J).
STING N153S Expression in RORgT+ Fetal LTi Cells Is
Sufficient to Interfere with LN and Peyer’s Patch
Development
RORgT expression during fetal development is restricted to LTi
cells (Sun et al., 2000), which act in concert with LTo cells to
Figure 6. RORgT-Cre-MediatedCell-Type-Specific Expression of STINGN153SDiminishesNumbers of Single-Positive TCells in the Thymus
and Spleen
(A) Schematic of the floxed-STOP STING N153S construct. Mice with Cre-dependent expression of the STING N153S gene in the ROSA locus (floxed-stop
STING N153S mice) were generated using transcription activator-like effector nucleases (TALENs).
(B) PCR amplification of transcriptional stop containing ROSA homology arms from double-negative (DN; CD8CD4) and double-positive (DP; CD8+CD4+)
thymocyte DNA from an adult RORgT-Cre+ floxed-STOP STING N153S mouse.
(C) Images of H&E staining on lungs of 13-week-old RORgT-Cre+ floxed-STOP STING N153S mice (right panel) and floxed-STOP STING N153S control animals
(left panel). n = 3 mice per genotype.
(D–H) Thymocytes from 3-to-4-week-old RORgT-Cre+ floxed-STOP STING N153S mice and floxed-STOP STING N153S control animals were harvested, and
single-cell suspensions were prepared for FACS analysis. (D) Representative FACS plots of CD4 and CD8 expression gated on CD45+CD19NK1.1 cells.
Percent and number of DN (E), DP (F), CD4+ (G), and CD8+ (H) cells. Data represent the mean of five mice per group pooled from two independent experiments.
(I–L) Splenocytes from 3-to-4-week-old RORgT-Cre-positive floxed-stop STINGN153Smice and floxed-stop STINGN153S control animals were harvested, and
single-cell suspensions were prepared for FACS analysis. Percent and number of CD3+ (I), CD4+ (J), CD8+ (K), and NK1.1+ (L) cells.
Data represent the mean of 10 mice per group pooled from at least two independent experiments. Results were analyzed by unpaired t test. *p < 0.05; **p < 0.01;
***p < 0.001; ****p < 0.0001.
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initiate LN and Peyer’s patch organogenesis (van de Pavert and
Mebius, 2010). We found that expression of STING N153S, spe-
cifically in RORgT+ LTi cells, was sufficient to prevent LN and
Peyer’s patch development based on visual assessment and
Evans blue staining of LNs (Figures 7A and 7B). However, we still
observed very small mesenteric LNs and occasionally a single
unilateral inguinal, brachial, or axillary LN in some animals that
express the STING N153S mutant in LTi cells (Figure 7B). The
sporadic presence of a residual LN despite the expression of
STING N153S in LTi cells might suggest additional effects of
STINGN153S on nonhematopoietic cells. Alternatively, sporadic
residual LNs might result from the incomplete excision of the
floxed-STOP by Cre, which would be expected to occur in a
small subset of LTi cells.
Postnatally, RORgT is expressed in mature ILC3s, including
LTi-like cells (Sawa et al., 2010; Sun et al., 2000; Takatori
et al., 2009). In the adult gut, we found that there was a
similar percentage and number of CD45+ cells in WT and
Figure 7. Expression of STING N153S in LTi
Cells Disrupts LN Development
(A) Representative photographs of inguinal LNs
after Evans Blue dye injection into the foot pad of
Cre-negative floxed-STOP STING N153S (left
panel) or RORgT-Cre-positive floxed-stop STING
N153S (right panel) animals.
(B) Quantitation of LNs and Peyer’s patches from
floxed-stop STING N153S and RORgT-Cre+
floxed-STOP STING N153S mice. n = 13–14.
(C–M) Leukocytes were harvested from the small
intestines of 3-to-4-week-old RORgT-Cre+ and
floxed-stop STING N153S animals and then
analyzed by flow cytometry. Percent (C) and total
number (D) of LinCD45+ cell (lineage markers:
CD3CD5CD19). Representative FACS plots (E)
of GATA3+ (ILC2), RORgT+ (ILC3), and
GATA3RORgT populations gated on LinCD45+
cells from floxed-STOP STING N153S (left panel)
and RORgT-Cre+ floxed-STOP STING N153S
(right panel) animals. Red text denotes percent of
cells in each gate, and blue text denotes the cell
population. Percent and total number (respec-
tively) of ILC3s (F and G), LTi-like cells (H and I),
NKp46+ ILC1 and NK cells (J and K), and ILC2 cells
(L and M).
Data represent the mean from 8–9 mice per ge-
notype. All data were pooled from at least two in-
dependent experiments. Results were analyzed by
unpaired t test. ***p < 0.001, ****p < 0.0001.
STING N153S animals. Cell-type-specific
expression of STING N153S in RORgT-
positive lineages caused a 95-fold
reduction in the number of ILC3s and a
91-fold reduction in the number of LTi-
like cells (Figures 7C–7I). There also was
a corresponding increase in the percent
of ILC1s and ILC2s, but no difference in
the total number of these cell types (Fig-
ures 7J–7M). Collectively, these results
demonstrate that the expression of
STING N153S in DP T cells, ILC3s, and LTi-like cells is sufficient
to reduce their numbers. Furthermore, our results suggest that
STING gain-of-function signaling can impact the differentiation
of progenitor cells as well as the lifespan of mature T cells and
ILCs. Finally, expression of STING N153S in fetal LTi cells is suf-
ficient to prevent the development of LNs and Peyer’s patches,
revealing a deleterious role of STING gain-of-function during
lymphoid tissue organogenesis in mice.
DISCUSSION
We discovered that the STING N153S gain-of-function muta-
tion disrupts LN and Peyer’s patch organogenesis and inter-
feres with LTi cell differentiation. Furthermore, we demon-
strated that expression of STING N153S in RORgT-positive
lineages is sufficient to interfere with the development of LNs
and Peyer’s patches. Thus, STING gain-of-function dysregu-
lates lymphoid tissue organogenesis in mice by interfering
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with the development of LTi cells and by reducing the numbers
of mature LTi cells.
An effect of STING gain-of-function in lymphoid tissue organ-
ogenesis was unexpected, especially since other pattern recog-
nition receptors have not been implicated in lymphoid tissue
organogenesis. Furthermore, the impact of STING signaling in
ILCs is incompletely understood (Canesso et al., 2018; Marcus
et al., 2018). Since CRISPR/Cas9 can sometimes produce off-
target effects (Cradick et al., 2013; Frock et al., 2015; Fu et al.,
2013; Hsu et al., 2013; Pattanayak et al., 2013; Wang et al.,
2015), one potential question regarding the LN deficiency
phenotype is whether a second mutation due to an off-target ef-
fect may be responsible for this particular defect. However, we
corroborated the LN deficiency phenotype in independently
generated STING N153S mice, and a similar defect was
observed but not studied in another STING gain-of-function
mouse that has a mutation in the neighboring amino acid (STING
V154M mice) (Bouis et al., 2019). LN deficiency also occurred in
our heterozygous transgenic mice that express the STING
N153S cDNA from the ROSA locus. It is unlikely that an off-target
mutation elsewhere in the genome could explain the universal
absence of LNs and Peyer’s patches in four independently
generated heterozygous mouse models.
We previously found that STING N153S is sufficient to cause
an immunodeficiency during viral infection that is more severe
than that of STING goldenticket mice, which lack functional
STING signaling. The immunodeficiency of STING N153S
mice is also more severe than that of Rag1/ animals, which
lack adaptive immunity (Bennion et al., 2019). Severe immuno-
deficiency in STING N153S mice distinguishes the animal
model from the disease associated with the analogous STING
N154S mutation in humans. In contrast to what we observed
in mice, patients with the STING N154S mutation have LNs
(Liu et al., 2014). In mice, the deficiency of ILCs, LNs, and
Peyer’s patches likely contributes to the severe immunodefi-
ciency phenotype, including IgA deficiency and a failure to
adequately produce virus-specific IgG. We previously found
that STING N153S dysregulates virus-specific CD8+ T cell re-
sponses after intranasal inoculation with gHV68, leading to
reduced gHV68-specific CD8+ T cell responses in the lung.
This might result from diminished antigen presentation as a
consequence of LN deficiency (Banchereau and Steinman,
1998). Finally, since CD4+ T cells in the spleen help B cells to
undergo antibody class switching (Victora and Nussenzweig,
2012), the absence of T cell zones in the spleen may explain
the impaired ability of STING N153S animals to produce vi-
rus-specific IgG (Bennion et al., 2019).
Development of LNs requires LTi cells, which represent a sub-
set of ILC3s (Artis and Spits, 2015; Eberl et al., 2004). We found
that there were fewer CD4+ LTi cells in STING N153S fetuses
compared to WT littermate fetuses, and this defect corre-
sponded with reduced CD4 staining in LN anlagen on E18.5.
Although RORgT lineage-restricted expression of STING
N153S blocked LN development, we cannot exclude contribu-
tions of STING N153S expression in other cell types. For
example, STING is also highly expressed in lymphatic endothe-
lial cells and may be expressed in LTo stromal cells (Heng et al.,
2008).
An open question is whether alterations in the quantity or qual-
ity of LTi cells may explain the LN deficiency in STING N153S
mice. LN anlagen develops as LTa on LTi cells ligates the
LTbR on stromal LTo cells (F€utterer et al., 1998; Rennert et al.,
1996; van de Pavert and Mebius, 2010). LTbR stimulation in-
duces noncanonical NF-kB signaling, which upregulates adhe-
sion molecules and chemokines to recruit more LTi cells as
well as T and B cells to the developing LN (Cupedo and Mebius,
2005; Dejardin et al., 2002; Ngo et al., 1999). Studies of LN devel-
opment in mice deficient in noncanonical NF-kB signaling have
suggested that LTi cell accumulation must exceed a threshold
level of cells for LN anlagen to develop and persist postnatally
(Kim et al., 2000; Onder et al., 2013). Our results are consistent
with the hypothesis that diminished numbers of LTi cells, below
a threshold, can cause LN deficiency. However, mice deficient
for the transcription factor Nfil3 also have reduced numbers of
LTi cells in the fetus, although Nfil3/ mice still develop LNs
(Xu et al., 2015). This may indicate that LTi cells are a heteroge-
nous population with only a subset of cells contributing to LN
development. In STING N153S mice, an alternative explanation
might be that the LTi cells, although reduced in number, also
are somehow unfit in their capacity to promote LN development.
An answer to this question will likely require more extensive
mechanistic phenotyping and subset analysis of LTi cells.
We found that SAVI patients have lower frequencies of circu-
lating ILCs in the blood. However, humans with STING gain-of
functions mutations have LNs (Liu et al., 2014). These species-
specific differences may reflect STING expression levels in ILC
subsets or, alternatively, differential effects of the STING mutant
in human and mouse cells. To better explain species-specific ef-
fects of STING gain-of-function on LN development, we would
have liked to assess LTi-like cells in SAVI patient samples. How-
ever, this was not possible, in part because ILC3s and LTi cells
are not readily detectable in circulation (Shikhagaie et al.,
2017). Future studies examining LTi and ILC3 cells from tonsils
or intestinal tissues from SAVI patients may help to further define
species-specific effects on these cell types.
Although we uncovered an immunological mechanism of LN
deficiency caused by STING gain-of-function, the molecular
mechanisms that underlie STING-N153S-mediated impairment
of ILCs remain elusive. STING gain-of-function mutations cause
pro-apoptotic and anti-proliferative effects in T cells (Cerboni
et al., 2017; Gui et al., 2019; Wu et al., 2019), and we observed
subtle effects on apoptosis in a cell culture differentiation system
of ILCs, but not in freshly isolated ILCs. If STING gain-of-function
induces apoptosis in ILCs, the effect appears to be subtle. Alter-
natively, STING N153S may cause ILC cytopenia via an alterna-
tive mechanism that remains to be identified.
Our group and others continue to pursue the molecular and
cellular effects of STING gain-of-function mutations (Cerboni
et al., 2017; Gui et al., 2019; Wu et al., 2019). Definitive reversal
of the physiological and immunological effects of STING gain-of-
function, which are established as type I IFN independent inmice
(Bouis et al., 2019; Luksch et al., 2019), will likely require charac-
terization of pathways that are less well understood, as well as
genetic approaches that rigorously confirm mechanism under
physiological conditions. This ongoing work may lead to a
greater understanding of WT and mutant STING biology, in
Cell Reports 31, 107771, June 16, 2020 11
Article
ll
OPEN ACCESS
addition to insights regarding fundamental mechanisms of LN
development and ILC differentiation and survival in humans
and in mice.
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Mouse anti-CD27 ThermoFisher RRID:AB_2722949
Mouse anti-CD90.2 ThermoFisher RRID:AB_2717157
Mouse anti-Tox ThermoFisher RRID:AB_10853657
Mouse anti-E4BP4 (NFIL3) ThermoFisher RRID:AB_11150965
Mouse anti-B220 Biolegend RRID:AB_492875
Mouse anti-VCAM1 R&D Biosystems RRID:AB_355499
Mouse anti-CD31 Biolegend RRID:AB_2629682
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Mouse anti-PDPN ThermoFisher RRID:AB_1106990
Mouse anti-B220 (biotin) Biolegend RRID:AB_312989
Mouse anti-Ter119 (biotin) Biolegend RRID:AB_313704
Mouse anti-GR1 (biotin) Biolegend RRID:AB_313368
Lymphotoxin beta receptor monoclonal antibody ThermoFisher RRID:AB_763451
Mouse anti-RelB Cell Signaling Technologies RRID:AB_2179173
Mouse anti-IkBa Cell Signaling Technologies RRID:AB_390781
Goat anti-rabbit IgG (H+L) secondary antibody, HRP ThermoFisher RRID:AB_228341
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CD159a (NKG2A)-VioBright FITC, human antibody Miltenyi Biotec RRID:AB_2726450
CD94-APC-Vio770, human antibody Miltenyi Biotec RRID:AB_2811494
CD127 Monoclonal Antibody (eBioRDR5),
PE-Cyanine7
ThermoFisher RRID:AB_1659672
PE/Dazzle 594 anti-human CD294 (CRTH2) BioLegend RRID:AB_2572052
Brilliant Violet 605 anti-human CD117 (c-kit) BioLegend RRID:AB_2562024
Brilliant Violet 650 anti-human CD16 BioLegend RRID:AB_11125578
Brilliant Violet 785 anti-human CD56 (NCAM) BioLegend RRID:AB_2566058
CD7 antibody BD Biosciences RRID:AB_10898348
CD2 antibody BD Biosciences RRID:AB_2744356
CD3 antibody BD Biosciences RRID:AB_2744390
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CD14 antibody BD Biosciences RRID:AB_2744285
BUV737 Mouse Anti-Human CD19 BD Biosciences RRID:AB_2716867
CD45 antibody BD Biosciences RRID:AB_2744401
Biological Samples
Human peripheral blood mononuclear cells Bénédicte Neven, Necker-
Enfants Malades Hospital
N/A
Human lymph nodes Bénédicte Neven, Necker-
Enfants Malades Hospital
N/A
Chemicals, Peptides, and Recombinant Proteins
Evans Blue Millipore Sigma Cat# E2129
Prolong Diamond Antifade Mountant with Dapi Fischer Cat# P36966
RIPA buffer Cell Signaling Technologies Cat# 9806S
Halt Protease Inhibitor ThermoFisher Cat# 78429
PierceTM ECL Substrate ThermoFisher Cat# 32106
Collagenase IV Sigma Cat# C5138
Intracellular Fixation and Permeabilization kit ThermoFisher Cat# 88-8824-00
Recombinant murine stem cell factor (SCF) Peprotech Cat# 250-03
Recombinant murine IL-7 Peprotech Cat# 217-17
Recombinant murine FLT3-ligand Peprotech Cat# 250-31L
Promega RNasin Plus Rnase Inhibitor Promega Cat# N2611
Annexin V Biolegend Cat# 640917
Annexin V BD Biosciences Cat# 556421
Critical Commercial Assays
Mouse IgA ELISA Kit Immunology Consultants
Laboratory, Inc
Cat# E90-A
FITC BrdU Flow Kit BD Biosciences Cat# 559619
Deposited Data
Single-cell RNA FACS-seq on WT and STING
N153S a4b7+ fetal liver (E14.5) cells
This paper Mendeley DOI: https://dx.doi.
org/10.17632/9nck2z26tf.1
Experimental Models: Cell Lines
OP9 cells ATCC Cat# CRL-2749
Experimental Models: Organisms/Strains
Mouse: CD45.1 mice (B6.SJL-Ptprca Pepcb/BoyJ) Jackson Laboratory Stock# 002014
Mouse: STING N153S mice Jackson Laboratory Stock# 033543
Mouse: Floxed-STOP STING N153S mice This paper N/A
Mouse: RORgt-Cre (B6.FVB-Tg(Rorc-cre)1Litt/J Jackson Laboratory Stock# 022791
Mouse: Rag1/ (B6.129S7-Rag1tm1Mom/J) Jackson Laboratory Stock# 002216
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RESOURCE AVAILABILITY
Lead Contact
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Jonathan
J. Miner (jonathan.miner@wustl.edu).
Materials Availability
All unique reagents generated in this study are available from the Lead Contact with a completed Materials Transfer Agreement.
Commercially available reagents are indicated in the Key Resources Table.
Data and Code Availability
The dataset generated by the single-cell FACs-Sequencing of a4b7+ fetal liver (E14.5) progenitor cells during this study is available at
Mendeley DOI: https://dx.doi.org/10.17632/9nck2z26tf.1
EXPERIMENTAL MODEL AND SUBJECT DETAILS
In vivo animal models
STING N153S mice were generated by our lab and published previously (Warner et al., 2017). All animals were housed in specific
pathogen free facilities at Washington University in St. Louis. All STING N153S expressing animals were heterozygous and aged
matched, co-housed littermate control animals were used for all experiments. Both sexes were used in all experiments and animals
were randomly assigned to experimental groups. Floxed-STOP STING N153S mice were generated by and obtained from the Hope
Center Transgenic Vectors Core at Washington University in Saint Louis. TALENs genome editing for the creation of transgenic mice
has been described previously (Meyer et al., 2010). Briefly, to generate mice that conditionally expressed the STING N153S protein a
targeting vector specific to the Rosa26 locus was assembled. This vector included a Rosa26 homology arm, a CAG promoter region,
a transcriptional stop sequence flanked by loxp sequences, the STING N153S cDNA sequence, and a second Rosa26 homology
arm. The targeting vector and TALENs were injected into C57BL/6J single-cell embryos obtained from superovulated C57BL/6J fe-
male mice mated to male C57BL/6J animals. Modified embryos were transferred into pseudo-pregnant female recipient mice. PCR
assays and DNA sequencing confirmed targeted insertion of the vector into the Rosa26 locus. Expression of the mutant STING
N153S protein was obtained by crossing heterozygous floxed-STOP STING N153S mice to RORgT-Cre-expressing animals. All
other mouse strains were obtained as indicated in the Key Resources Table. Power analysis was conducted for Institutional Animal
Care and Use Committee-approved in vivo studies in order to determine the number of animals needed per experimental group. At
Continued
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Mouse: Ifnar1/ Hwang et al., 1995 N/A
Mouse: cGas/ (B6(C)-Cgastm1d(EUCOMM)Hmgu/J Jackson Laboratory Stock# 026554
Mouse: Irf3/ Sato et al., 2000 N/A
Mouse: Irf7/ Honda et al., 2005 N/A
Oligonucleotides
CCL19 primers: 50CAGACAGGCAGCAGTCTT-30 &
50-GTGGCCTGCCTCAGATTAT-30
Integrated DNA Technologies N/A
CCL21 primers: 50TTCTTCTGGCTGTACTTAAGGC-30 &
50-TGATGACTCTGAGCCTCCTTAG-30
Integrated DNA Technologies N/A
Cxcl13 PrimeTime qPCR Assay Integrated DNA Technologies Assay ID: Mm.PT.58.31389616
Vcam1 PrimeTime qPCR Assay Integrated DNA Technologies Assay ID: Mm.PT.58.9687546
Icam1 PrimeTime qPCR Assay Integrated DNA Technologies Assay ID: Mm.PT.58.43714327
Madcam1 PrimeTime qPCR Assay Integrated DNA Technologies Assay ID: Mm.PT.58.28611018
Cxcl10 PrimeTime qPCR Assay Integrated DNA Technologies Assay ID: Mm.PT.58.43575827
Software and Algorithms
ImageJ Schneider et al., 2012 https://imagej.nih.gov/ij/
GraphPad Prism 8 GraphPad https://www.graphpad.com
Other
EasySep Mouse Streptavidin RapidSpheres Isolation Kit STEMCELL Technologies Cat# 19860
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least two independent experiments were conducted to replicate findings. No outliers were excluded from analyses. The age and
number of animals used for each experiment is listed in the figure legends.
SAVI patient samples
ILCs were analyzed from blood samples drawn from a total of 5 patients with STING gain-of-function mutations (V155M, N154S, or
R281Q). There were 2males (2 years-old, V155M and 10 years-old, N154S) and 3 females (8 years-old, V155M, 24 years-old, V155M,
and 10 years old, R281Q). Four patients were on a JAK1/2 inhibitor, and one patient was on mycophenolate mofetil. For ethical rea-
sons, SAVI patients were not removed from medical treatments. Hilar lymph nodes were obtained from SAVI patients (1 male, 1 fe-
male, both age 14) who underwent lung transplantation. Written informed consent (parental consent, in case of minors) was obtained
from all participants of the study. The study and protocols conform to the 1975 Declaration of Helsinki and were approved by the
comité de protection des personnes Ile de France II and the French advisory committee on data processing in medical research.
Cell lines
OP9 cell lines were used in the co-culture of mouse primary bone marrow cells. OP9 cell lines were cultured in MEM-amedium sup-
plemented with 20% FCS and 1% penicillin/streptomycin (OP9 medium) at 37C in a humidified atmosphere at 5% CO2.
METHOD DETAILS
Quantitation of lymph nodes
Bilateral cervical, inguinal, brachial, and axillary lymph nodes as well as mesenteric lymph nodes from WT and STING N153S mice
were dissected and the number of discernible nodes counted. A string of mesenteric lymph nodes was counted as one lymph node.
For Evans Blue staining of lymphatics and lymph nodes,micewere anesthetized and 25 mL of 5%Evans Blue dye in PBSwas injected
into 1 forefoot and 1 hindfoot. Fifteen minutes after Evans Blue injection, mice were euthanized and dissected for lymph node visu-
alization and quantitation (Harrell et al., 2008). Any sign of a lymph node, regardless of size, was counted. To quantitate Peyer’s
patches, the small intestine was divided into proximal, middle, and distal segments, and quantitated visually. For adoptive transfer
studies, splenocytes were isolated from adult WTmice and single cell suspensions were obtained after disruption of tissue through a
70-mmfilter. After erythrocyte lysis in ACK buffer, splenocytes were washed and counted. 5million bulk splenocytes were transferred
into Rag1–/– STING N153S or Rag1–/– animals via intravenous injection. Mice were euthanized 3.5 weeks later, and Evans Blue stain-
ing was used to aid in quantitation of lymph nodes and Peyer’s patches.
Inguinal fat pad and intestine histology
Inguinal fat pads (and attached abdominal skin) were harvested at the bifurcation of the superficial epigastric vein (approximately
1 cm diameter). Small intestines were removed and flushed with PBS to remove any fecal matter. Tissues were fix in 4% paraformal-
dehyde for 24 hours and then embedded in paraffin. Inguinal fat pads were sequentially sectioned with 20 sectioned analyzed per
mouse. Small intestines were serially sectioned with at least 48 sections analyzed per mouse.
Quantitation of IgA
IgA levels in the serum and stool were determined using a commercial mouse IgA ELISA kit (Immunology Consultants Laboratory
catalog no. E-90A) according to the manufacturer’s protocol. All fecal samples were weighed and then suspended in sterile PBS
at 100 mL per 10 mg, vortexed, and then spun down and supernatant transferred to new tube. Samples were diluted 1:300 and
then analyzed.
Spleen and fetal tissue immunofluorescence
Fetuses were harvested on E18.5, and spleens were harvested from adult mice (7-16 weeks old). Tissues were immediately
embedded in OCT, frozen on dry ice and stored at 80C. Sections (8-mm) were cut at 20C and then stored at 80C until
time of staining. At the time of staining, sections were removed from freezer and fixed in ice-cold acetone for 15 minutes, washed
with PBS, and blocked for 10 minutes. Primary antibodies were applied overnight at 4C and secondary antibodies were applied
for 1 hour at room temperature. Coverslips were mounted using Prolong Diamond Antifade Mountant with Dapi (Fisher Cat#
P36966). Images were taken using a Zeiss Axio Imager M2 Plus Wide Field Fluorescence Microscope. Antibodies used: CD4
(Biolegend catalog no. 100401), Madcam1 (R&D Biosystems catalog no. AF993), CD3 (Biolegend Cat# 100243), B220 (Biolegend
catalog no. 103229), VCAM-1 (R&D Biosystems catalog no. AF643). Quantitation of staining intensity was performed using ImageJ
and normalized to the area analyzed.
Splenic stromal cell analysis
Isolation of follicular dendric cells (FDC), fibroblastic reticular cells (FRC), and endothelial cells was performed as previously
described (Sato et al., 2016). Briefly, spleens were harvested and digested using a cocktail of Collagenase D, DNase I, and
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Dispase I. Digested spleens were filtered, washed, and then enriched for FDCs and FRCs by negatively selecting for CD45– B220–
Ter119– cells. Cells were washed and then stained with antibodies against CD45, CD19, CD31 (clone 390), PDPN (clone eBio8.1.1),
CD54 (clone 3e2), and CD21/35 (clone 7e9).
Gene expression analysis
Total RNA from spleen homogenates or MEFs was isolated using the RNeasy kit (QIAGEN) per the manufacturer’s protocol. TaqMan
RNA-to-Ct 1-Step kit (Applied Biosystems) was used to measure mRNA expression. Primer and probe assays were obtained from
Integrated DNA Technologies. DDCt values were calculated and then normalized to the mock WT samples. All samples analyzed
were normalized to the house keeping gene (GAPDH). Samples where the target gene did not amplify were assigned a CT value
of 38 as the limit of detection.
Noncanonical NF-kB signaling in MEFs
For studies of noncanonical NF-kB signaling, primary MEFS were stimulated with 2 mg/ml of anti-LTbR antibody (clone eBio3C8) for
24 hours. Cells were then harvested and analyzed by western blot or qRT-PCR.
SDS-PAGE and western blot
PrimaryMEFswere lysed in RIPA buffer (CST, catalog no. 9806S) supplemented with a protease inhibitor (Thermo Fisher, catalog no.
78430) and phosphatase inhibitor (Thermo Fisher, catalog no. 88667). An equal amount of protein was loaded and separated on 10%
SDS-PAGE gels (Bio-Rad), then transferred to polyvinylidene fluoride membranes (EMD Millipore). Primary antibody against RelB
(clone C1E4), IkBa (clone L34A5), and GAPDHwere stained and detected by the use of horseradish-peroxidase-conjugated second-
ary anti-rabbit antibody (Invitrogen, catalog no. 31460). All the blots were performed using PierceTM ECL Substrate (Thermo Fisher
Scientific) and scanned with a ChemiDocTM Touch Imaging System (Bio-Rad).
Flow cytometric analysis of leukocytes
For analysis of intestinal leukocytes, small intestines were harvested, flushed, and opened longitudinally, and Peyer’s patches were
removed. Epithelial cells were removed via two rounds of gentle agitation with HBSS containing 10% FBS, 150 mM HEPES, and
5 mM EDTA. Tissues were washed with HBSS and digested with Collagenase IV (Sigma C5138) by shaking in a 37C incubator
for 40 minutes. Digested tissues were filtered through 100-mm filters and cellular debris removed via Percoll gradient for flow cyto-
metric analysis. Single-cell suspensions were stained for CD45 (Invitrogen: clone 30-F11), NKp46 (Invitrogen: clone 29A1.4), CD4
(eBioscience: clone GK1.5), CCR6 (BD Biosciences: clone 140706), and lineage (Lin) markers, which consist of CD3ε (Biolegend:
clone 145-2C11), CD5 (Biolegend: clone 53-7.3), CD19 (Biolegend: clone 6D5). Intracellular staining for RORgT (eBioscience: clone
AFKJS-9) and GATA3 (BD Biosciences: clone L50-823) was performed according to eBioscience’s Intracellular Fixation and Perme-
abilization kit (Thermo Fischer Scientific: catalog no. 88-8824-00) before analysis on a Fortessa X-20. For analysis of bone marrow
leukocytes, femurs and tibias of adult mice were collected and flushed with PBS for collection of bone marrow. Bone marrow was
filtered, red blood cells lysed, and remaining cells were washed and resuspended for FACS analysis. Single-cell suspensions were
stained with antibodies against lineage markers CD19, CD5, TER119 (Biolegend: clone TER119), B220 (Biolegend: clone RA3-6B2),
CD11b (Biolegend: clone M1/70), CD11c (Biolegend: clone N418), NK1.1 (Biolegend: clone PK136), CD4 (Biolegend: clone Gk1.5),
CD3ε, CD8a (Biolegend: clone 53-6.7), GR1 (Biolegend: clone RB6-8C5), Ly6G (Biolegend: clone 1A8), TCRg/d (Biolegend: clone
GL3), CD45, CD127 (Biolegend: clone A7R34), FLT3 (Biolegend: clone A2F10), cKIT (Biolegend: clone ACK2), CD25 (Biolegend:
clone 3C7) a4b7 (Biolegend: clone DATK32), PLZF (Invitrogen: clone Mags.21F7), ID2 (Invitrogen: clone ILCID2), CD27 (Invitrogen:
clone LG.7F9), CD244 (Invitrogen: clone eBio244F4), CD122 (Invitrogen: clone TM-b1), and fixable live dead stain (Biolegend catalog
no. 423105 or Thermo Fisher catalog no. L34965).
Isolation of fetal gut and fetal liver cells
Fetal livers were harvested at E13.5-14.5 and mechanically dissociated using a 1 mL pipette before being passed through a 70-mm
filter. Cells were washed and resuspended for flow cytometric analysis. Fetal gut cells were isolated as described previously (Bando
et al., 2015). Briefly, mouse fetuses were harvested at E16.5-18.5, and the small intestine was removed. Intestinal tissue was minced
and then digested in complete RPMImedia and collagenase at 37C for 25minutes while shaking at 200 rpm. Following digestion, the
tissue was dissociated in Gentlemacs tubes (Milteny Biotec catalog no. 130-096-334). Dissociated tissue was filtered through a 70-
mm filter into a 50 mL conical tube and cell suspension was washed with cold FACS buffer (4% FBS in PBS). For in vivo BrdU labeling
of fetal gut cells, 0.1mg/gram of bodyweight BrdUwas injected into a pregnant dam. Two-hours post BrdU injection, fetal livers were
harvested as described above.
LTi cell differentiation assays
In vitro LTi cell differentiation was described previously (Cherrier et al., 2012). Briefly, one day prior to sorting, OP9 cells were plated
into 24-well plates at a density of 3.0 3 104 cells per well. Fetal livers were harvested on E13.5-E14.5, and single-cell suspensions
were obtained. Negative selection was performed to remove CD3+, Ter119+, Gr-1+, and CD11c+ cells, and then
CD3-CD19-B220-Gr1-CD45+cKITintCD127+a4b7+ cells were sorted and 1000 fetal liver progenitor cells were plated onto OP9
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stromal cells along with 10 ng/ml of rSCF (Peprotech catalog no. 250-03) and rIL-7 (Peprotech catalog no. 217-17). A half-media
change was performed on days 4 and 11. Cells were passaged onto new OP9 stromal cells on day 7. Analysis by flow cytometry
was performed 6 or 14 days after sorting and co-culture.
Single-cell RNA-seq
E14.5 fetal liver cells were prepared according to the established protocols that have been previously described for LTi cell isolation.
Single Lin–CD45+cKITintCD127+a4b7+ cells were sorted directly into a 96-well plate (one cell per well) containing 2 mL of 10x lysis
buffer (Takara catalog no. 635013) and 5% RNase inhibitor (Promega catalog no. PRN2611). After sorting, plates were immediately
frozen at 80C. Single-cell RNA sequencing of each well was performed at the Genome Technology Access Center (GTAC) at
Washington University in St. Louis. Data are available at Mendeley DOI: https://dx.doi.org/10.17632/9nck2z26tf.1
Flow cytometric analysis of human PBMCs
Isolation of human PBMCs was performed using a Ficoll-Paque gradient. Cells were stained for the following markers: CD159a
(NKG2A) (Miltenyi Biotec: VioBright FITC, clone REA110), CD294 (CRTH2) (BioLegend: PE-Dazzle594, clone BM16), CD127 (IL-
7R) (Thermo Fisher: PE-Cy7, clone eBioRDR5), CD7 (BD Biosciences: Alexa Fluor 700, clone M-T701), CD94 (Miltenyi Biotec:
APC-Vio770 clone REA113), CD117 (c-Kit) (BioLegend: BV605, clone 104D2), CD16 (BioLegend: BV605, clone 3G8), CD56 (Bio-
Legend: BV785, clone 5.1H11), CD2 (BD Biosciences: BUV395, clone RPA-2.10), CD45 (BD Biosciences: BUV805, clone HI30),
and lineage markers consisting of CD3 (BD Biosciences: BUV737, clone UCHT1), CD5 (BD Biosciences: BUV737, clone UCHT2),
CD14 (BD Biosciences: BUV737, clone M5E2) and CD19 (BD Biosciences: BUV737, SJ25C1). Human serum IgG was used to block
Fc receptors (Sigma-Aldrich). Surface membrane staining was performed using Brilliant Stain Buffer (BD Biosciences). Dead cells
were excluded using the fixable viability dye eFluor506 (Thermo Fisher). Cells were fixed with 2% PFA prior to acquisition on a
BD LSRFortessa (BD Biosciences) and subsequent analysis with FlowJo 10 (BD Biosciences)
Histopathology of SAVI patient lymph nodes
During lung transplantation, mediastinal lymph nodes from explanted lungs were retrieved and analyzed. Biopsies were fixed in 10%
neutral buffered formalin, embedded in paraffin and stained with hematoxylin-eosin. Immunohistochemical staining was performed
on an automated stainer (Bond Max; Leica Biosystems).
QUANTIFICATION AND STATISTICAL ANALYSIS
Unless otherwise specified, all data were analyzed using GraphPad Prism software by Mann-Whitney or unpaired t test as specified
in the figure legends. Flow cytometry data were analyzed using Cytobank or FlowJo v10.4.1.
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Figure S1. Quantitation of lymph nodes after adoptive transfer and flow cytometric analysis of ILCs in WT and STING N153S 
animals. Related to Figure 1. (A) Representative photographs of Rag1-/- (left panel) and Rag1-/- STING N153S (right panel) animals 
following adoptive transfer of WT splenocytes. (B) Total number of discernible inguinal, brachial, axillary, and mesenteric lymph nodes 
and Peyer’s patches after adoptive transfer of WT splenocytes. Data represent the mean of 9 mice per genotype. Results were analyzed 
by Mann-Whitney test. (C-E) Flow cytometric analysis on splenocytes from WT and STING N153S littermate mice. (C) Representative 
FACS plots depicting ILC1 and NK cell populations gated on CD45+CD3-B220- splenocytes. Total number of ILC1s (D) and NK cells (E) 
in the spleens of STING N153S and WT mice. Data were collected from 8 mice per genotype. Results were analyzed by unpaired t test. 
(F-M) Bone marrow was collected from adult mice. Representative FACS plots of Lin-CD127+ bone marrow cells (F) from WT (top panels) 
and STING N153S (bottom panels) littermate mice. Lineage markers for bone marrow ILC progenitor stains include: TER119, B220, 
CD19, CD11b, CD11c, NK1.1, CD4, CD3e, CD8a, GR1, Ly6G, and TCRg/d. Total number of bone marrow cells recovered (G). Total 
numbers of aLP cells (Lin-CD127+a4b7+FLT3-CD25-) (H), CHILP1 cells (Lin-CD127+a4b7+FLT3-CD25-ID2+PLZF-) (I), and CHILP2 cells 
(Lin-CD127+a4b7+FLT3-CD25-ID2+PLZF+) (J). Representative FACS plots (K) of WT (left panel) and STING N153S (right panel) CD3-
CD19-NK1.1-CD11b- CD244+CD27+cKITintCD127+ cells. Total numbers of Pre-NKp (L) and Refined NKp cells (M). n = 9 mice per 
genotype and data were analyzed by unpaired t test. All data were generated from at least 2 independent experiments. *, P < 0.05; **, P 
< 0.01; ***, P < 0.001; ****, P < 0.0001. 
 
 
 
Table S1. STING N153S lymph node deficiency in mice lacking downstream effectors of STING, the type I IFN receptor (IFNAR1), 
and cGAS. Related to Figure 1. STING N153S mice were crossed to Ifnar1-/-, Irf3-/- Irf7-/-, or cGas-/- animals. Adult STING N153S animals 
deficient for the indicated genes were sacrificed and examined for visual evidence of mesenteric, inguinal, brachial, and axillary lymph 
nodes and Peyer’s patches. Quantitation of the number of discernible lymph nodes compared to littermate controls (e.g., control animals 
expressing WT STING). Number of Peyer’s patches are reported as the mean number observed per mouse. Data were collected from 3-
6 mice per genotype in at least 2 independent experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S2. Splenic organization, but not noncanonical NFkB signaling, is perturbed in STING N153S mice. Related to Figure 1. 
(A) H&E staining of paraffin embedded WT (left panel) and STING N153S (right panel) spleen sections. (B) MADCAM1 expression 
(green) in WT (left panel) and STING N153S (right panel) OCT embedded spleen sections (5µm). (C) B220 (red) and CD3 (green) 
expression in WT (left panel) and STING N153S (right panel). Scale bar equals 100 µm. Images are representative of 3 images collected 
from 3 mice per genotype. (D) Gating strategy for splenic stromal cell populations. (E-G) FACS quantitation of the percent and number 
of follicular dendritic cells (E), fibroblastic reticular cells (F) and endothelial cells (G). Data represent the mean of 6 mice per genotype. 
(H) mRNA was isolated from spleen homogenates, and gene expression was quantitated by qRT-PCR for Ccl19, Ccl21, and Cxcl13. 
Data represent the mean of 8 spleens per genotype. Data in (E-G) were analyzed by unpaired t test and data in (H) were analyzed by 
Mann-Whitney test. (I-M) STING N153S and WT littermate primary MEFs were stimulated with 2 µg/ml anti-LTbR antibody for 24 hours 
followed by SDS-PAGE, Western blot, or RNA isolation and qRT-PCR analysis. Representative Western blot (I) analysis of IkBa (top 
panel), RelB (middle panel, top band) and GAPDH from 3 independent generated primary MEF lines per genotype. qRT-PCR analysis of 
gene expression levels in primary MEFs (J-M). Data represent the mean of 6 samples per genotype and are reported as the fold change 
relative to control-treated MEFs. All data were pooled from at least 2 independent experiments. Results were analyzed by Mann-Whitney 
test. *, P < 0.05; **, P < 0.01; ****, P < 0.0001. 
 
 
Figure S3. Single-cell RNA-seq analysis of type I IFN-stimulated gene and LTi associated gene expression in WT and STING 
N153S a4b7+ cells. Related to Figure 3. Fetal livers from WT and heterozygous STING N153S animals were harvested on E14.5, 
and a4b7+ cells underwent single-cell FACS sorting into 96-well plates, followed by RNA sequencing. (A) Indicated type I IFN-stimulated 
genes and (B) LTi cell-associated genes as measured by FACS-seq analysis of WT and STING N153S a4b7+ progenitor cells. Data 
represent the mean number of counts per gene from 48 cells per genotype performed as a single gene expression screen. Results were 
analyzed by Mann-Whitney test. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S4. STING N153S fetal liver a4b7+ progenitor cells do not efficiently differentiate into LTi cells after 14 days in an OP9 
cell culture system. Related to Figure 4. a4b7+ progenitor cells from the fetal liver were co-cultured with OP9 stromal cells, SCF, and 
IL-7. Cells were allowed to differentiate for 14-days and analyzed by FACS.  (A) Representative FACS plots of adult WT (left panels) and 
STING N153S (right panels) CD45+CD3-CD19- cells. Cell frequencies within each gate are denoted in red and cell population names are 
labeled in blue. (B) Average frequencies of ILC and a4b7+ cell populations. (C-H) Percent and number of ILC1 (C), NK cells (D), ILC2 
(E), ILC3 (F), LTi-like cells (G), and Lin- CD45+ cells (H). Data represent the mean of 8-15 replicates per group pooled from at least 2 
independent experiments. Results were analyzed by unpaired t test. **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. 
 
 
Figure S5. Apoptosis and proliferation in WT and STING N153S LTi and LTi progenitor cells. Related to Figure 4. (A-D) Flow 
cytometric analysis of fetal liver cells from E13.5-E14.5 STING N153S and WT fetuses.  Representative dot plots gated on Lin-(CD3, 
CD5, and CD19) CD45+cKITintCD127+a4b7+ cells (A). Percent and number of live annexin V+ CD127+a4b7+ cells (B). Percent and number 
of live annexin V- CD127+a4b7+ cells (C). Percent and number of BrdU+CD127+a4b7+RORgT+ (LTi) cells (D). Data represent the mean of 
6-12 mice per group pooled from at least 2 independent experiments.  (E-G) a4b7+ progenitor cells from the fetal liver were co-cultured 
with OP9 stromal cells, SCF, and IL-7. Cells were allowed to differentiate for 6 days and analyzed by FACS. Representative dot plots 
gated on total cells (E). Percent of annexin V+ live (F) and annexin V+ dead (G) cells from total cells analyzed. Data represent the mean 
of 5-9 mice per group pooled from 2 independent experiments. Results were analyzed by unpaired t test. *, P < 0.05; **, P < 0.01; ***, P 
< 0.001. 
 
 
 
 
 
 
 
Figure S6. SAVI patient lymph node histology. Related to Figure 5. Representative images of SAVI patient lymph nodes stained with 
(A) hematoxylin & eosin, or (B) anti-CD20. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S7. Flow cytometric analysis of double negative T cells in the thymus as well as B cells and myeloid cells in the spleens 
of RORgT-Cre+ floxed-STOP STING N153S mice. Related to Figure 6. (A-D) Percent and number of DN1 (A), DN2 (B), DN3 (C), and 
DN4 cells (D) in the thymus of floxed-STOP STING N153S and RORgT-Cre+ floxed-STOP STING N153S mice. Flow cytometric analysis 
of splenocytes. (E) Percent and total number of CD45+ cells. (F-H) Percent and number of B220+ B cells (F), Ly6G+ neutrophils (G) and 
CD11b+ inflammatory monocytes (H). (I) Representative FACS plots of floxed-STOP STING N153S (left panels) and RORgT-Cre+ floxed-
STOP STING N153S (right panels) CD45+Ly6G- cells. (J) Percent and number of CD11c+ dendritic cells. Data represent the mean of 5 
mice per group pooled from 2 independent experiments. Results were analyzed by unpaired t test. *, P < 0.05; ****, P < 0.0001. 
